| Name | CaCCinh-A01 |
| Description | CaCCinh-A01 is an inhibitor of the calcium-activated chloride channel (CaCC, 10 μM) and TMEM16A (IC50: 2.1 μM). |
| Cell Research | Each well of a 96-well plate is washed three times with PBS (200 μL/wash), leaving 50 μL of PBS. Test compounds (including CaCCinh-A01) (0.5 μL) are added to each well at 25 μM final concentration. After 10 min, 96-well plates are transferred to a plate reader for fluorescence assay. Each well is assayed individually for TMEM16A-mediated I- influx by recording fluorescence continuously (400 ms/point) for 2 s (baseline), then 50 μL of a 140 mM I-solution containing 200 μM ATP is added. |
| In vitro | Tannic acid (100 μM) and CaCCinh-A01 (30 μM) effectively inhibit CaCC current following ATP stimulation[1]. CaCCinh-A01 (0.1/1/10 μM) reduces Calcium-dependent chloride current (38±14, 66±10, and 91±1%). ATP-induced short-circuits currents are reduced by 38±7 and 78±3% at 10 and 30 μM CaCCinh-A01, respectively. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.76 mM), Sonication is recommended. DMSO : 55 mg/mL (158.31 mM), Sonication is recommended.
|
| Keywords | TMEM16A | neurological | Inhibitor | inhibit | infarction | deficit | Cl? Channels | Chloridechannel | Chloride Channel | Chloride channel | cerebral artery occlusion | CaCCinh-A-01 | CaCCinh-A01 | CaCCinhA01 | CaCCinh A01 | CaCC |
| Inhibitors Related | Selamectin | D-Alanine | Niflumic acid | Urethane | Lubiprostone | Flufenamic acid | Halothane | Betaine chloride | Afoxolaner | Fenamic acid | Meticrane | Adjudin |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Compound Library |